drugset / Trial / NCT04386057

LY3214996 +/- HCQ in Pancreatic Cancer

NCT04386057

RandomizedParallel-groupOpen-labelTreatment

Summary

This study is evaluating the safety and efficacy of combining the study drug LY3214996 with hydroxychloroquine sulfate (HCQ) in patients with advanced pancreatic cancer.

Timeline

Start
2020-05-27
Primary completion
2023-08-09
Completion
2024-02-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydroxychloroquine Small molecule Oral
Subject TEMUTERKIB Small molecule Oral